0\" encoding=\"UTF-8\"?>\n<table frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th align=\"left\"><bold>Indication</bold></th><th align=\"left\"><bold>Clinically isolated syndrome</bold></th><th colspan=\"2\" align=\"left\"><bold>Relapsing-remitting MS</bold></th></tr></thead><tbody valign=\"top\"><tr><td align=\"left\" valign=\"bottom\">Escalation therapy<hr/></td><td align=\"left\" valign=\"bottom\"> <hr/></td><td colspan=\"2\" align=\"left\" valign=\"bottom\">Natalizumab<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"> <hr/></td><td align=\"left\" valign=\"bottom\"> <hr/></td><td colspan=\"2\" align=\"left\" valign=\"bottom\">Fingolimod (depending on other risk factors: anti-JCV antibody status, diabetes mellitus, cardiac problems)<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"> <hr/></td><td align=\"left\" valign=\"bottom\"> <hr/></td><td colspan=\"2\" align=\"left\" valign=\"bottom\">Failure to other treatments (e.g. mitoxantrone, cyclophosphamide)<hr/></td></tr><tr><td rowspan=\"3\" align=\"left\" valign=\"top\">Baseline therapy</td><td align=\"left\" valign=\"bottom\">Glatiramer acetate<hr/></td><td align=\"left\" valign=\"bottom\">Glatiramer acetate<hr/></td><td align=\"left\" valign=\"bottom\"><italic>Highly active patients</italic>:<hr/></td></tr><tr><td rowspan=\"2\" align=\"left\" valign=\"top\">Interferon</td><td rowspan=\"2\" align=\"left\" valign=\"top\">Interferon</td><td align=\"left\" valign=\"bottom\">Natalizumab<hr/></td></tr><tr><td align=\"left\">Fingolimod</td></tr></tbody></table>\n"}, "text": "Indication\tClinically isolated syndrome\tRelapsing-remitting MS\t \tEscalation therapy\t \tNatalizumab\t \t \t \tFingolimod (depending on other risk factors: anti-JCV antibody status, diabetes mellitus, cardiac problems)\t \t \t \tFailure to other treatments (e.g. mitoxantrone, cyclophosphamide)\t \tBaseline therapy\tGlatiramer acetate\tGlatiramer acetate\tHighly active patients:\t \tInterferon\tInterferon\tNatalizumab\t \tFingolimod\t \t", "sentences": [], "annotations": [], "relations": []}, {"offset": 21414, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Regional recommendations", "sentences": [], "annotations": [], "relations": []}, {"offset": 21439, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "Figures 3, 4 and 5 show the algorithm developed during the discussion. Natalizumab is recommended as an escalation therapy in patients with breakthrough disease on the basis of its established efficacy in Phase III studies. In highly active MS, natalizumab is considered as a first-line therapy for naive patients with disabling relapses in association with MRI activity. Several factors including prior immunosuppressant therapy, anti-JCV antibody status and patient choice may contribute to the selection of natalizumab. A complete blood count and a cranial MRI scan (within 3 months of starting natalizumab therapy) are recommended at baseline. This enables comparison with subsequent scans that may be done to investigate the cause of new or worsening neurological symptoms once on natalizumab therapy. Figure 3 shows recommendations for maximising the safety of natalizumab. Treatment should be stopped if hypersensitivity reactions or persistent anti-drug antibodies occur. If infusion reactions occur, treatment can be continued with monitoring and pre-medication. Treatment is discontinued in the event of non-response, pregnancy, suspicion of PML, definite adverse events or a change in the benefit-risk evaluation. A low threshold to withhold natalizumab and investigate with MRI and CSF testing is recommended when a diagnosis of possible PML is entertained. If a thorough neurological assessment cannot rule out PML, natalizumab must be suspended and not restarted until a disorder other than MS has been excluded with confidence. Natalizumab can be resumed only if the diagnosis of PML is discounted.", "sentences": [], "annotations": [], "relations": []}, {"offset": 23058, "infons": {"file": "1471-2377-14-27-3.jpg", "id": "F3", "section_type": "FIG", "type": "fig_caption"}, "text": "Regional recommendations for maximising safety of natalizumab. CBC: complete blood count; CSF: cerebrospinal fluid; JCV: John Cunningham virus; LFTs: liver function tests; PML: progressive multifocal leukoencephalopathy.", "sentences": [], "annotations": [], "relations": []}, {"offset": 23279, "infons": {"file": "1471-2377-14-27-4.jpg", "id": "F4", "section_type": "FIG", "type": "fig_caption"}, "text": "Regional recommendations for using natalizumab in anti-JCV antibody-negative patients. JCV: John Cunningham virus.", "sentences": [], "annotations": [], "relations": []}, {"offset": 23394, "infons": {"file": "1471-2377-14-27-5.